|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre L, Bray F, Siegel R, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J,
Xue Y, Suo J, Tao K, He X, et al: Morbidity and mortality of
laparoscopic versus open D2 distal gastrectomy for advanced gastric
cancer: A randomized controlled trial. J Clin Oncol. 34:1350–1357.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Irani S, Baron T, Itoi T and Khashab M:
Endoscopic gastroenterostomy: Techniques and review. Curr Opin
Gastroenterol. 33:320–329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu T, Hu X, Wei P and Shan G: Molecular
background of the regional lymph node metastasis of gastric cancer.
Oncol Lett. 15:3409–3414. 2018.PubMed/NCBI
|
|
6
|
Walkiewicz K, Gętek M, Muc-Wierzgoń M,
Kokot T and Nowakowska-Zajdel E: The importance of ADAM family
proteins in malignant tumors. Postepy Hig Med Dosw (Online).
70:67–73. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brown RV, Gaerig VC, Simmons T and Brooks
TA: Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15
promoter as new molecular targets for breast cancer therapeutics.
Molecules. 18:15019–15034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pham D, Kim J, Kim S, Shin D, Uong N, Hyun
H, Yoon MS, Kang SJ, Ryu YJ, Cho JS, et al: Effects of ADAM10 and
ADAM17 inhibitors on natural killer cell expansion and
antibody-dependent cellular cytotoxicity against breast cancer
cells in vitro. Anticancer Res. 37:5507–5513. 2017.PubMed/NCBI
|
|
9
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin H, Diaz A, Blouin L, Lebbink R, Patena
W, Tanbun P, LeProust EM, McManus MT, Song JS and Ramalho-Santos M:
Systematic identification of barriers to human iPSC generation.
Cell. 158:449–461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nyren-Erickson E, Jones J, Srivastava D
and Mallik S: A disintegrin and metalloproteinase-12 (ADAM12):
Function, roles in disease progression, and clinical implications.
Biochim Biophys Acta. 1830:4445–4455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolfsberg T, Straight P, Gerena R, Huovila
A, Primakoff P, Myles D and White JM: ADAM, a widely distributed
and developmentally regulated gene family encoding membrane
proteins with a disintegrin and metalloprotease domain. Dev Biol.
169:378–383. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohtsuka T, Shiomi T, Shimoda M, Kodama T,
Amour A, Murphy G, Ohuchi E, Kobayashi K and Okada Y: ADAM28 is
overexpressed in human non-small cell lung carcinomas and
correlates with cell proliferation and lymph node metastasis. Int J
Cancer. 118:263–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Le Pabic H, Bonnier D, Wewer U, Coutand A,
Musso O, Baffet G, Clément B and Théret N: ADAM12 in human liver
cancers: TGF-beta-regulated expression in stellate cells is
associated with matrix remodeling. Hepatology. 37:1056–1066. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin H, Zhong F, Ouyang Y, Wang Q, Ding L
and He S: Upregulation of ADAM12 contributes to accelerated cell
proliferation and cell adhesion-mediated drug resistance (CAM-DR)
in Non-Hodgkin's Lymphoma. Hematology. 22:527–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu M, Zhou H, Zhang C, He J, Wei H, Zhou
M, Lu Y, Sun Y, Ding JW, Zeng J, et al: ADAM17 promotes
epithelial-mesenchymal transition via TGF-β/Smad pathway in gastric
carcinoma cells. Int J Oncol. 49:2520–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cerretti D, DuBose R, Black R and Nelson
N: Isolation of two novel metalloproteinase-disintegrin (ADAM)
cDNAs that show testis-specific gene expression. Biochem Biophys
Res Commun. 263:810–815. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei X, Moncada-Pazos A, Cal S,
Soria-Valles C, Gartner J, Rudloff U and Lin JC; NISC Comparative
Sequencing Program; Rosenberg SA, López-Otín C and Samuels Y:
Analysis of the disintegrin-metalloproteinases family reveals
ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat.
32:E2148–E2175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Li Y, Li L, Chen M, Zhang C, Zuo
X, Zhou FS, Liang B, Zhu J, Li P, et al: Association study of
susceptibility loci with specific breast cancer subtypes in Chinese
women. Breast Cancer Res Treat. 146:503–514. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Purrington K, Slager S, Eccles D,
Yannoukakos D, Fasching P, Miron P, Carpenter J, Chang-Claude J,
Martin NG, Montgomery GW, et al: Genome-wide association study
identifies 25 known breast cancer susceptibility loci as risk
factors for triple-negative breast cancer. Carcinogenesis.
35:1012–1019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao M, Jia W, Jiang W, Wang P, DU G,
Cheng S and Song M: ADAM29 expression in human breast cancer and
its effects on breast cancer cells in vitro. Anticancer Res.
36:1251–1258. 2016.PubMed/NCBI
|
|
23
|
Brim H, Abu-Asab M, Nouraie M, Salazar J,
Deleo J, Razjouyan H, Mokarram P, Schaffer AA, Naghibhossaini F and
Ashktorab H: An integrative CGH, MSI and candidate genes
methylation analysis of colorectal tumors. PloS One. 9:e821852014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ashktorab H, Schäffer A, Daremipouran M,
Smoot D, Lee E and Brim H: Distinct genetic alterations in
colorectal cancer. PloS One. 5:e88792010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Costa N, Paulo P, Caffrey T, Hollingsworth
M and Santos-Silva F: Impact of MUC1 mucin downregulation in the
phenotypic characteristics of MKN45 gastric carcinoma cell line.
PloS One. 6:e269702011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SG and Hwang SH: The association
between the duration of fluoropyrimidine-based adjuvant
chemotherapy and survival in stage II or III gastric cancer. World
J Surg Oncol. 14:1022016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu H, Ye L, Mansel RE, Zhang Y and Jiang
WG: Clinical implications of the influence of Ehm2 on the
aggressiveness of breast cancer cells through regulation of matrix
metalloproteinase-9 expression. Mol Cancer Res. 8:1501–1512. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Micocci KC, Moritz MN, Lino RL, Fernandes
LR, Lima AG, Figueiredo CC, Morandi V and Selistre-de-Araujo HS:
ADAM9 silencing inhibits breast tumor cells transmigration through
blood and lymphatic endothelial cells. Biochimie. 128–129:174–182.
2016. View Article : Google Scholar
|
|
30
|
Mężyk-Kopeć R, Wyroba B, Stalińska K,
Próchnicki T, Wiatrowska K, Kilarski WW, Swartz MA and Bereta J:
ADAM17 promotes motility, invasion, and sprouting of lymphatic
endothelial cells. PLoS One. 10:e01326612015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Motycková M, Zák P, Vroblová V, Andrýs C,
Belada D, Malý J and Smolej L: Prognostic markers in chronic
lymphocytic leukemia. Vnitr Lek. 57:847–857. 2011.PubMed/NCBI
|
